We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Index Generated for Diagnosing Non-Alcoholic Fatty Liver Disease

By LabMedica International staff writers
Posted on 31 Jan 2017
Print article
Image: Researchers have developed an extended fatty liver index (FLI) that can better diagnose fatty liver and better determine the probability of reducing liver fat content during a lifestyle intervention (Photo courtesy of Institute for Diabetes Research and Metabolic Diseases, Germany).
Image: Researchers have developed an extended fatty liver index (FLI) that can better diagnose fatty liver and better determine the probability of reducing liver fat content during a lifestyle intervention (Photo courtesy of Institute for Diabetes Research and Metabolic Diseases, Germany).
Based on clinical data, researchers have generated a new fatty liver index (FLI) that can predict the presence of fatty liver disease (FLD) with high accuracy, enabling development of an extended, more effective diagnostic index for nonalcoholic fatty liver disease (NA-FLD), which has become an epidemic in industrialized countries.

There is not only a great interest worldwide to understand the causes and consequences of FLD, but also to diagnose it at an early stage. Under the direction of Professor Norbert Stefan, researchers of the Department of Internal Medicine IV of Tübingen University Hospital and the Institute for Diabetes Research and Metabolic Diseases (IDM) of Helmholtz Zentrum München as well as of the German Institute for Nutrition and Health (DIfE), both partners of the German Center for Diabetes Research, succeeded in improving on the current diagnostic index.

Approximately every third adult in the industrialized countries has a morbidly fatty liver. For these people, this not only increases the risk of advanced liver diseases such as liver cirrhosis and liver cancer, but also in particular type 2 diabetes and cardiovascular diseases. To be able to intervene early with preventive and therapeutic measures, the fatty liver must be detected in time. The ultrasound liver examination and the determination of the liver values are suitable, but in most cases they can only diagnose the fatty liver in an advanced stage. More sophisticated tests such as magnetic resonance spectroscopy are more meaningful, but they are not widely applicable because of the relatively high costs in clinical practice.

Therefore, scientists are working on simple accurate diagnostic methods that would be more suitable. Among various indices that have been developed, the Fatty Liver Index (FLI) consisting of the parameters age, waist circumference, and triglyceride levels (TG) measured in the blood in a fasting state, and gamma-glutamyl transpeptidase (GGT), has been shown to be quite effective.

The researchers from Tübingen led by Prof. Stefan, in collaboration with Prof. Schulze of DIfE, and their colleagues from Hamburg and Italy, have developed an improved FLI. For this purpose, in addition to the parameters of the FLI, they used the TG and glucose levels from an oral glucose tolerance test measured at the time point of 2 hours, as well as the most important gene variant for fatty liver (rs738409 C>G in PNPLA3). On the basis of data from the TULIP (Tübingen Lifestyle Intervention Program) study, they were able to show that with this new, extended FLI, not only can the fatty liver be diagnosed better than with the known FLI, but also the probability of reducing liver fat content during a lifestyle intervention can be more precisely determine.

We hope that “this index will be increasingly used in clinical practice to diagnose fatty liver disease at an early stage in order to prevent the consequences of fatty liver disease,” said Prof. Stefan.

The study, by Kantartzis K et al, was published online January 14, 2017, in the journal Diabetes & Metabolism.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.